H M McDonald1, P Brocklehurst, A Gordon. 1. Women's and Children's Hospital, Microbiology and Infectious Diseases, 72 King William Road, North Adelaide, South Australia, Australia, 5006. helen.mcdonald@cywhs.sa.gov.au
Abstract
BACKGROUND: Bacterial vaginosis is an imbalance of the normal vaginal flora with an overgrowth of anaerobic bacteria and a lack of the normal lactobacillary flora. Bacterial vaginosis during pregnancy has been associated with poor perinatal outcome and, in particular, preterm birth (PTB). Identification and treatment may reduce the risk of PTB and its consequences. OBJECTIVES: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (May 2006). SELECTION CRITERIA: Randomized trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora. DATA COLLECTION AND ANALYSIS: Two review authors assessed trials and extracted data independently. We contacted study authors for additional information. MAIN RESULTS: We included fifteen trials of good quality, involving 5888 women. Antibiotic therapy was effective at eradicating bacterial vaginosis during pregnancy (Peto odds ratio (OR) 0.17, 95% confidence interval (CI) 0.15 to 0.20; 10 trials, 4357 women). Treatment did not reduce the risk of PTB before 37 weeks (Peto OR 0.91, 95% CI 0.78 to 1.06; 15 trials, 5888 women), or the risk of preterm prelabour rupture of membranes (PPROM) (Peto OR 0.88, 95% CI 0.61 to 1.28; four trials, 2579 women). However, treatment before 20 weeks' gestation may reduce the risk of preterm birth less than 37 weeks (Peto OR 0.63, 95% CI 0.48 to 0.84; five trials, 2387 women). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (Peto OR 0.83, 95% CI 0.59 to 1.17, five trials of 622); however, it may decrease the risk of PPROM (Peto OR 0.14, 95% CI 0.05 to 0.38) and low birthweight (Peto OR 0.31, 95% CI 0.13 to 0.75)(two trials, 114 women). In women with abnormal vaginal flora (intermediate flora or bacterial vaginosis) treatment may reduce the risk of PTB before 37 weeks (Peto OR 0.51, 95% CI 0.32 to 0.81; two trials, 894 women). Clindamycin did not reduce the risk of PTB before 37 weeks (Peto OR 0.80, 95% CI 0.60 to 1.05; six trials, 2406 women). AUTHORS' CONCLUSIONS: Antibiotic treatment can eradicate bacterial vaginosis in pregnancy. This review provides little evidence that screening and treating all pregnant women with asymptomatic bacterial vaginosis will prevent PTB and its consequences. However, there is some suggestion that treatment before 20 weeks' gestation may reduce the risk of PTB. This needs to be further verified by future trials.
BACKGROUND:Bacterial vaginosis is an imbalance of the normal vaginal flora with an overgrowth of anaerobic bacteria and a lack of the normal lactobacillary flora. Bacterial vaginosis during pregnancy has been associated with poor perinatal outcome and, in particular, preterm birth (PTB). Identification and treatment may reduce the risk of PTB and its consequences. OBJECTIVES: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (May 2006). SELECTION CRITERIA: Randomized trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora. DATA COLLECTION AND ANALYSIS: Two review authors assessed trials and extracted data independently. We contacted study authors for additional information. MAIN RESULTS: We included fifteen trials of good quality, involving 5888 women. Antibiotic therapy was effective at eradicating bacterial vaginosis during pregnancy (Peto odds ratio (OR) 0.17, 95% confidence interval (CI) 0.15 to 0.20; 10 trials, 4357 women). Treatment did not reduce the risk of PTB before 37 weeks (Peto OR 0.91, 95% CI 0.78 to 1.06; 15 trials, 5888 women), or the risk of preterm prelabour rupture of membranes (PPROM) (Peto OR 0.88, 95% CI 0.61 to 1.28; four trials, 2579 women). However, treatment before 20 weeks' gestation may reduce the risk of preterm birth less than 37 weeks (Peto OR 0.63, 95% CI 0.48 to 0.84; five trials, 2387 women). In women with a previous PTB, treatment did not affect the risk of subsequent PTB (Peto OR 0.83, 95% CI 0.59 to 1.17, five trials of 622); however, it may decrease the risk of PPROM (Peto OR 0.14, 95% CI 0.05 to 0.38) and low birthweight (Peto OR 0.31, 95% CI 0.13 to 0.75)(two trials, 114 women). In women with abnormal vaginal flora (intermediate flora or bacterial vaginosis) treatment may reduce the risk of PTB before 37 weeks (Peto OR 0.51, 95% CI 0.32 to 0.81; two trials, 894 women). Clindamycin did not reduce the risk of PTB before 37 weeks (Peto OR 0.80, 95% CI 0.60 to 1.05; six trials, 2406 women). AUTHORS' CONCLUSIONS: Antibiotic treatment can eradicate bacterial vaginosis in pregnancy. This review provides little evidence that screening and treating all pregnant women with asymptomatic bacterial vaginosis will prevent PTB and its consequences. However, there is some suggestion that treatment before 20 weeks' gestation may reduce the risk of PTB. This needs to be further verified by future trials.
Authors: M A Klebanoff; J C Carey; J C Hauth; S L Hillier; R P Nugent; E A Thom; J M Ernest; R P Heine; R J Wapner; W Trout; A Moawad; K J Leveno; M Miodovnik; B M Sibai; J P Van Dorsten; M P Dombrowski; M J O'Sullivan; M Varner; O Langer; D McNellis; J M Roberts Journal: N Engl J Med Date: 2001-08-16 Impact factor: 91.245
Authors: M R Joesoef; S L Hillier; G Wiknjosastro; H Sumampouw; M Linnan; W Norojono; A Idajadi; B Utomo Journal: Am J Obstet Gynecol Date: 1995-11 Impact factor: 8.661
Authors: Hyagriv N Simhan; Marijane A Krohn; James M Roberts; Adriana Zeevi; Steve N Caritis Journal: Am J Obstet Gynecol Date: 2003-10 Impact factor: 8.661
Authors: S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao Journal: N Engl J Med Date: 1995-12-28 Impact factor: 91.245
Authors: Mark A Klebanoff; John C Hauth; Cora A MacPherson; J Christopher Carey; R Phillips Heine; Ronald J Wapner; Jay D Iams; Atef Moawad; Menachem Miodovnik; Baha M Sibai; J Peter vanDorsten; Mitchell P Dombrowski Journal: Am J Obstet Gynecol Date: 2004-02 Impact factor: 8.661
Authors: Ronald F Lamont; Chia-Ling Nhan-Chang; Jack D Sobel; Kimberly Workowski; Agustin Conde-Agudelo; Roberto Romero Journal: Am J Obstet Gynecol Date: 2011-04-02 Impact factor: 8.661
Authors: Patricia Weidlich; Carlos Heitor C Moreira; Tiago Fiorini; Marta L Musskopf; José M da Rocha; Maria Lucia R Oppermann; Anne M Aass; Per Gjermo; Cristiano Susin; Cassiano K Rösing; Rui V Oppermann Journal: Clin Oral Investig Date: 2013-01 Impact factor: 3.573
Authors: Edward P Acosta; Peta L Grigsby; Kajal B Larson; Amanda M James; Mary C Long; Lynn B Duffy; Ken B Waites; Miles J Novy Journal: J Infect Dis Date: 2013-10-31 Impact factor: 5.226
Authors: Camille H Raynes Greenow; Christine L Roberts; Jane C Bell; Brian Peat; Gwendolyn L Gilbert; Sharon Parker Journal: Cochrane Database Syst Rev Date: 2011-09-07
Authors: Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens Journal: BMC Pregnancy Childbirth Date: 2010-02-23 Impact factor: 3.007
Authors: Renato Passini; Ricardo P Tedesco; Sergio T Marba; Jose G Cecatti; Ruth Guinsburg; Francisco E Martinez; Marcelo L Nomura Journal: BMC Pregnancy Childbirth Date: 2010-05-19 Impact factor: 3.007